title: Severe symptoms following a massive intentional L-thyroxine ingestion.
abstract: L-Thyroxine (T4) is commonly prescribed medication for hypothyroidism in humans and animals. Overdose has generally resulted in limited symptomatology managed with sedatives and beta-adrenergic receptor antagonists. We describe the largest acute T4 ingestion ever reported, which resulted in a profound thyrotoxicosis, resistant to treatment. A 34-y-old man ingested 900 (0.8 mg) tablets of veterinary T4 (720 mg) and was given 60 g of activated charcoal. He became lethargic on post-ingestion days 2 and 3; had vomiting, diaphoresis and insomnia on day 4; on day 5 he "looked like he had too much coffee", began "using a lot of words" and became agitated, assaultive and stopped speaking intelligibly; and on day 6 returned to the hospital combative and confused. He was diaphoretic, mydriatic, hyperreflexic, tremulous, with clear lungs and active bowel sounds, and received activated charcoal, haloperidol, diazepam, and phenobarbital, and was tracheally intubated. During hospitalization he was rehydrated, treated with propranolol and diazepam, but remained continuously tachycardic. On day 12 he became afebrile and his tachycardia resolved. Free T4 levels ranged from > 13 mcg/dL on day 6 to 1.2 mcg/dL on day 12. By discharge (day 15) he had lost 20 kilograms of body weight, but was clinically euthyroid 2 w later. This case suggests that large intentional T4 ingestions should be managed differently than current T4 overdose protocol.
authors.affiliation: NYC Poison Center, NY 10016, USA.
authors.forename: J B
authors.initials: JB
authors.lastname: Hack
authors.forename: J A
authors.initials: JA
authors.lastname: Leviss
authors.forename: L S
authors.initials: LS
authors.lastname: Nelson
authors.forename: R S
authors.initials: RS
authors.lastname: Hoffman
mesh_terms: D000328:Adult; D000931:Antidotes / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D002606:Charcoal / Q000627:therapeutic use*; D003975:Diazepam / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D007442:Intubation, Intratracheal; D008297:Male; D010634:Phenobarbital / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D013610:Tachycardia / Q000188:drug therapy*; D013971:Thyrotoxicosis / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D013974:Thyroxine / Q000506:poisoning*
chemical_list: D000931:Antidotes; D002606:Charcoal; D011433:Propranolol; D006220:Haloperidol; D003975:Diazepam; D013974:Thyroxine; D010634:Phenobarbital